Full history for every metric is available with a Kvantra account
Inari Medical, Inc. (NARI)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 7 | 51 | 140 | 277 | 383 | 494 | 574 |
| Operating profit | $m | -14 | -48 | |||||
| Net profit | $m | -10 | -2 | 14 | 10 | -29 | -2 | -79 |
| EPS reported | $ | -0.03 | -1.35 | |||||
| Operating cashflow per share | $ | 0.63 | 0.63 | |||||
| Capex per share | $ | 0.11 | 0.11 | |||||
| FCF per share | $ | 0.52 | 0.52 | |||||
| Free cash flow | $m | 30 | 2 | |||||
| Net debt | $m | -115 | -112 | |||||
| Book value equity | $m | 465 | 435 | |||||
| Book value per share | $ | 8.19 | 7.45 | |||||
| Number of shares | m | 56.77 | 58.37 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 7.93 | 10.77 | |||||
| P/S LTM | x | 7.47 | 8.15 | |||||
| P/FCF LTM | x | 123.98 | 2,962.26 | |||||
| EV/EBITDA LTM | x | 242.25 | -126.44 | |||||
| EV/Sales LTM | x | 7.45 | 7.96 | |||||
| Earnings Yield LTM | % | -0.04% | -0.04% | |||||
| FCF Yield | % | 0.81% | 0.03% | |||||
| Quality | ||||||||
| ROE | % | -0.35% | -0.37% | |||||
| ROIC | % | 0.90% | 0.90% | |||||
| Operating margin | % | -2.84% | -2.84% | |||||
| Gross margin | % | 88.03% | 88.03% | |||||
| FCF/Sales | % | 6.02% | 6.02% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +28.73% | +22.41% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | -94.62% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.93 | 0.05 | |||||
| Net Debt/EBITDA | x | -0.43 | -0.43 | |||||
| EBIT/Net interest | x | -71.59 | -71.59 | |||||
| Net debt/market cap | % | -3.13% | -2.38% | |||||
| Net debt/Equity | x | -0.25 | -0.26 | |||||
| Gross debt/equity | x | 0.07 | 0.08 | |||||
Company overview
Inari Medical, Inc. is a medical technology firm focused on creating, producing, promoting, and distributing devices for the minimally invasive management of venous conditions within the United States. Their product portfolio includes ClotTriever, a mechanical thrombectomy solution designed to extract significant clots from major blood vessels, specifically targeting deep vein thrombosis. Another key offering is FlowTriever, a substantial catheter-based aspiration and mechanical thrombectomy system, which addresses pulmonary embolism. The company also provides FlowSaver; FlowStasis, a large-bore suture retention device to manage venous access points; and FlowTriever 2, an enhanced version with a new disk design for efficiently capturing wall-adherent clots and reducing procedure time. Founded in 2011, the company was initially known as Inceptus Newco1 Inc. before rebranding as Inari Medical, Inc. in September 2013. Its corporate headquarters are located in Irvine, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Inari Medical, Inc. (NARI)
Inari Medical, Inc. is a medical technology firm focused on creating, producing, promoting, and distributing devices for the minimally invasive management of venous conditions within the United States. Their product portfolio includes ClotTriever, a mechanical thrombectomy solution designed to extract significant clots from major blood vessels, specifically targeting deep vein thrombosis. Another key offering is FlowTriever, a substantial catheter-based aspiration and mechanical thrombectomy system, which addresses pulmonary embolism. The company also provides FlowSaver; FlowStasis, a large-bore suture retention device to manage venous access points; and FlowTriever 2, an enhanced version with a new disk design for efficiently capturing wall-adherent clots and reducing procedure time. Founded in 2011, the company was initially known as Inceptus Newco1 Inc. before rebranding as Inari Medical, Inc. in September 2013. Its corporate headquarters are located in Irvine, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free